EXECUTIVE ENGAGEMENTS
POOL
8719
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1221
Interactions with Platform & by Email
PARTICIPANTS
262
Unique # Participated
VALIDATIONS
91
Responses Validated*
COMPANIES
163
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
212
PAGES
344
EDITION
17
PRICE
USD 5450
CODE
MCP-6313
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Amid the COVID-19 crisis, the global market for Neurodegenerative Drugs estimated at US$43.7 Billion in the year 2020, is projected to reach a revised size of US$64.6 Billion by 2027, growing at a CAGR of 5.7% over the analysis period 2020-2027. Multiple Sclerosis, one of the segments analyzed in the report, is projected to record a 6.1% CAGR and reach US$43.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Parkinson`s segment is readjusted to a revised 5.2% CAGR for the next 7-year period.
The Neurodegenerative Drugs market in the U.S. is estimated at US$11.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.7 Billion by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 5.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.
In the global Alzheimer`s segment, USA, Canada, Japan, China and Europe will drive the 4.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3.6 Billion in the year 2020 will reach a projected size of US$4.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.7 Billion by the year 2027, while Latin America will expand at a 5.7% CAGR through the analysis period.
SELECT PLAYERS
Biogen, Inc.; Boehringer Ingelheim GmbH; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; H. Lundbeck A/S; Merck KGaA; Mitsubishi Tanabe Pharma Corporation; Novartis International AG; Pfizer, Inc.; Reata Pharmaceuticals, Inc.; Sage Therapeutics, Inc.; Sanofi; Teva Pharmaceutical Industries Ltd.; UCB SA
SEGMENTS
» Disease Indication (Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA), Other Disease Indications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Neurodegenerative Drugs – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Parkinson`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Alzheimer`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy (SMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Spinal Muscular Atrophy (SMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Spinal Muscular Atrophy (SMA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Neurodegenerative Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| JAPAN |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| CHINA |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| EUROPE |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| FRANCE |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| GERMANY |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| SPAIN |
| Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| RUSSIA |
| Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| AUSTRALIA |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E) |
| Australia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| INDIA |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E) |
| India Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| SOUTH KOREA |
| South Korea Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| LATIN AMERICA |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E) |
| Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Neurodegenerative Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027 |
| Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| ARGENTINA |
| Argentina Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| BRAZIL |
| Brazil Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| MEXICO |
| Mexico Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| REST OF LATIN AMERICA |
| Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| MIDDLE EAST |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E) |
| Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Neurodegenerative Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027 |
| Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| IRAN |
| Iran Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| ISRAEL |
| Israel Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| SAUDI ARABIA |
| Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| UNITED ARAB EMIRATES |
| UAE Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| REST OF MIDDLE EAST |
| Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| AFRICA |
| Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E) |
| Africa Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 163 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com